Adaptive Biotech director plans sale of 9,615 shares

Adaptive Biotechnologies Corp (symbol ADPT) received a Rule 144 notice from director Katherine E. Owen covering a planned sale of up to 9,615 shares of common stock.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp (symbol ADPT) received a Rule 144 notice from director Katherine E. Owen covering a planned sale of up to 9,615 shares of common stock. The shares are associated with restricted stock awards granted in 2022, 2023, and 2025 and are to be sold through Morgan Stanley Smith Barney LLC. The filing reports an aggregate market value of approximately $249,990 for the shares, with an approximate sale date of August 26, 2026 on NASDAQ.

Key Figures

Shares to be sold: 9,615 shares of common stock Aggregate market value: $249,990.00 Restricted stock grant 03/17/2022: 1,110 shares +2 more

5 metrics

Shares to be sold 9,615 shares of common stock Maximum number of Adaptive Biotechnologies shares covered by the Rule 144 notice

Aggregate market value $249,990.00 Aggregate market value of the 9,615 shares covered by the planned sale

Restricted stock grant 03/17/2022 1,110 shares Common stock underlying a restricted stock award dated March 17, 2022

Restricted stock grant 01/26/2023 6,689 shares Common stock underlying a restricted stock award dated January 26, 2023

Restricted stock grant 03/04/2025 1,816 shares Common stock underlying a restricted stock award dated March 4, 2025

Key Terms

Rule 144, Restricted Stock, aggregate market value, Form 144

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock financial

"Common | 03/17/2022 | Restricted Stock | Issuer"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 9615 | 249990.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for ADPT?

It discloses that director Katherine E. Owen has filed a Rule 144 notice for the potential sale of up to 9,615 shares of Adaptive Biotechnologies common stock, with an aggregate market value of about $249,990, to be sold through Morgan Stanley Smith Barney LLC.

How many ADPT shares are covered by Katherine Owen’s planned Rule 144 sale?

The notice covers up to 9,615 shares of Adaptive Biotechnologies common stock, tied to three restricted stock awards granted in 2022, 2023, and 2025.

What is the aggregate market value of the ADPT shares in this Form 144?

The filing states an aggregate market value of approximately $249,990 for the 9,615 Adaptive Biotechnologies shares covered by the planned sale.

When are the ADPT shares expected to be sold under this Form 144?

The approximate sale date reported is August 26, 2026, which is when the 9,615 shares of Adaptive Biotechnologies common stock may be sold on NASDAQ under Rule 144.

What types of ADPT securities are involved in Katherine Owen’s Form 144?

The securities are common stock of Adaptive Biotechnologies issued as restricted stock from grants dated March 17, 2022, January 26, 2023, and March 4, 2025.

Which broker is handling the planned ADPT Rule 144 sale?

The planned sale of Adaptive Biotechnologies shares is listed as being handled by Morgan Stanley Smith Barney LLC Executive Financial Services at One New York Plaza, New York.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:14 PM Accepted by SEC EDGAR 08/26/2026 - 04:13 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001852578
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ADAPTIVE BIOTECHNOLOGIES CORPORATION
SEC File Number	001-38957
Address of Issuer	1165 Eastlake Avenue East Seattle WASHINGTON 98109
Phone	(206) 659-0067
Name of Person for Whose Account the Securities are To Be Sold	KATHERINE E OWEN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9615	249990.00	159595842	08/26/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/17/2022	Restricted Stock	Issuer			1110	03/17/2022	Not Applicable
Common	03/04/2025	Restricted Stock	Issuer			1816	03/04/2025	Not Applicable
Common	01/26/2023	Restricted Stock	Issuer			6689	01/26/2023	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Katherine Einterz Owen
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)